On March 18, YIDU TECH (02158) once again disclosed a share repurchase, spending over HK$6.5 million to buy back company shares on that day. According to company announcements, the firm has conducted a total of 32 repurchases since the start of the year, with cumulative expenditures exceeding HK$220 million. To date, the proportion of treasury shares to total share capital has risen to approximately 4.5%, setting a new company record and placing it among the top Hong Kong-listed companies in terms of treasury share ratio. Market convention suggests that consistent share buybacks by a listed company are often interpreted as a signal that management views the stock price as undervalued. An increase in treasury shares also provides greater flexibility for future capital operations, such as equity incentive plans and mergers and acquisitions. Since February 26, YIDU TECH has executed buybacks on 15 trading days. Among small to mid-cap companies, its repurchase frequency and cumulative investment amount are notably prominent. Analysts believe such actions reflect management's view that the current share price does not fully reflect the company's intrinsic value. Notably, the company has also made substantive progress in deploying its AI healthcare products. Reports indicate that YIDU TECH's clinical evidence-based intelligent agent, "Yidu Zhixun," has begun clinical application validation at several medical institutions, including Sun Yat-sen University Cancer Center, covering 15 cancer types such as lung cancer, breast cancer, liver cancer, and colorectal cancer. Following an internal test involving over 6,000 medical professionals, the "Yidu Zhixun" app version is set to launch, providing clinical workers access to this professional auxiliary tool. In terms of international expansion, YIDU TECH recently signed a strategic cooperation agreement with Guangxi Medical University and related institutions to jointly establish the Guangxi Medical Artificial Intelligence Research Institute. This initiative aims to promote the application of "AI + healthcare" in Guangxi and the ASEAN region. The collaboration is designed to implement the company's existing technological achievements in Guangxi and facilitate technology export and application cooperation with ASEAN countries. Recent developments show that while continuing its capital market repurchases, the company is also intensifying efforts in clinical validation of AI products and advancing international cooperation. This combined strategy has attracted significant attention within Hong Kong's technology sector, with the market anticipating further business implementation and value realization.